GleamWall
中文EN

ZIVO Zivo Bioscience, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1101026 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY164.5%
TTM net income YoY38.0%
TTM EPS YoY45.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin31.7%
Operating margin-4,045.7%
Net margin-4,059.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,608.6%
ROIC (approx.)—
Asset turnover0.40x

Leverage & solvency

Liabilities / assets687.5%
Debt / equity—
Current ratio0.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-1,025.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue$157,220$27,650
Cost of revenue$108,268$16,040
Gross profit$48,952$11,610
R&D expense$3.13M$1.38M
SG&A expense$10.28M$5.90M
Operating income-$13.36M-$7.26M
Interest expense—$23,793
Net income-$13.38M-$7.78M
EPS (diluted)-4.23-4.60
Dividends declared per share—3.11
Weighted avg. shares (diluted)3.17M1.69M
Balance sheet
Cash & equivalents$1.54M$274,380
Current assets$1.64M$425,377
PP&E, net—$0
Total assets$1.64M$555,715
Current liabilities$2.04M$2.76M
Short-term debt$0$0
Total liabilities$2.16M$2.76M
Shareholders' equity-$514,898-$2.21M
Shares outstanding3.62M2.38M
Cash flow statement
Operating cash flow-$4.31M-$5.80M
Investing cash flow$0$0
Financing cash flow$5.58M$4.28M
Stock-based compensation$1.51M$89,502

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.